Information for Patients
How TIMOPTIC® in OCUDOSE® Works
TIMOPTIC® works by reducing the level of IOP.
Preservative-free Sterile Ophthalmic Solution TIMOPTIC® is supplied in OCUDOSE®, a clear, individual, unit dose container.1
- TIMOPTIC® in OCUDOSE® is available in concentrations of 0.25 and 0.5 percent1
- Each individual unit contains 0.2 mL of solution, and should be used immediately after opening for administration1
The usual starting dose is one drop of 0.25 percent TIMOPTIC® in OCUDOSE® in the affected eye(s) twice a day1
Patients should apply enough gentle pressure to the individual container to obtain a single dose of the solution.1
When first starting a patient on treatment, TIMOPTIC® in OCUDOSE® should be taken twice a day, since some patients require more time for their IOP to stabilize. After four weeks, you should evaluate your patient’s IOP.1
- If IOP is maintained at satisfactory levels, dosage administration can be changed to one drop per day in the affected eye(s)
The most frequent side effects reported with use of TIMOPTIC® in OCUDOSE® were burning and stinging upon installation.1
Please view the full Prescribing Information for additional side effects that were reported less frequently.
TIMOPTIC® in OCUDOSE® is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration.
Click here to report any side effects that your patient may have experienced while using TIMOPTIC® in OCUDOSE®.
INDICATIONS AND USAGE
Preservative-free TIMOPTIC® in OCUDOSE® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC® in OCUDOSE® may be used when a patient is sensitive to the preservative in Timoptic (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.
IMPORTANT SAFETY INFORMATION
Timoptic is contraindicated in patients with: bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to any component of this product.
This drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Severe respiratory or cardiac reactions, including death, have been reported following systemic or ophthalmic administration of timolol maleate. Timoptic should be used with caution in patients with cerebrovascular insufficiency.
The most frequently reported adverse experiences have been burning and stinging upon instillation.
Please see full Prescribing Information by clicking on the link above.
Reference: 1. Timoptic (timolol maleate ophthalmic solution) in Ocudose (dispenser) [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2009.